Research & Development

MSD and Quotient collaborate on IBD drug targets

Merck & Co (MSD) has signed a multi-year research collaboration with Quotient Therapeutics to discover new drug targets for inflammatory bowel disease (IBD) using the latter’s somatic genomics platform technology.

Monash University and ClinChoice partner on new therapies development

Australia-based Monash University and ClinChoice have announced a strategic partnership to accelerate clinical development of new therapies.

Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody

Sanofi has signed an exclusive global licence agreement with Kali Therapeutics for KT501, a new tri-specific antibody for B cell-mediated autoimmune diseases.

ImmunityBio receives Macau approval for Anktiva combo therapy

ImmunityBio has received approval from the Pharmaceutical Administration Bureau (ISAF) of the Macau Special Administrative Region, China, for Anktiva (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for bladder cancer.

Novartis to acquire SNV4818 from Synnovation

Novartis has signed an agreement to acquire SNV4818, a pan-mutant selective Phosphoinositide 3-kinase alpha (PI3Kα) inhibitor, from Synnovation Therapeutics.

Congruence secures $39.5m to advance small molecule correctors pipeline

Congruence Therapeutics has announced the completion of a $39.5m financing round to advance its portfolio of small molecule correctors into the clinic.

R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia

R1 Therapeutics has raised $77.5m in an oversubscribed Series A funding to advance AP306 for hyperphosphatemia in chronic kidney disease (CKD) patients.

FDA issues CRL to Aldeyra’s reproxalap drug application

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Aldeyra Therapeutics for its new drug application (NDA) of reproxalap to treat dry eye disease.

Sentynl and PRG partner for Progerinin licence

Zydus Lifesciences subsidiary Sentynl Therapeutics has signed an agreement with Korean company PRG S&T to license Progerinin (SLC-D011), an investigational molecule intended to treat Hutchinson-Gilford Progeria Syndrome (HGPS).